The aim of our study was to describe the radiologic findings of extensive acute lung injury associated with limited thoracic irradiation. Limited thoracic irradiation occasionally results in acute lung injury. In this condition, chest radiograph shows diffuse ground-glass appearance in both lungs and thin-section CT scans show diffuse bilateral ground-glass attenuation with traction bronchiectasis, interlobular septal thickening and intralobular smooth linear opacities.
Acute Disease ; Adenocarcinoma/radiotherapy ; Adenocarcinoma/pathology ; Adenocarcinoma/drug therapy ; Adenocarcinoma/complications* ; Carcinoma, Squamous Cell/radiotherapy ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/complications* ; Journal Article ; Human ; Lung/radiation effects* ; Lung/pathology ; Lung Neoplasms/radiotherapy ; Lung Neoplasms/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/complications* ; Male ; Middle Age ; Radiation Injuries/radiography ; Radiation Injuries/pathology ; Radiation Injuries/etiology* ; Thorax/radiation effects

Trousseau's syndrome comsists of migratory thrombophlebitis and thromboembolic disorders of the venous and arterial systems in a malignancy or occult cancer. The overall incidence has been reported to vary from 1 to 11%. Pancreatic, lung, prostate, and stomach cancer is associated with the greatest risk of thromboembolic events. We encountered a 49-year-old man who presented with painful swelling of his lower legs. The chest radiograph showed increased opacity of the Left middle lung fields and Doppler sonography showed a thrombus in the left superficial femoral vein. Chest Computed Tomography showed a 5cm sized left hilar mass invading the pericardium with lymphadenopathy. The bronchoscope biopsy demonstrated an adenocarcinoma of the lung. Platinum based chemotherapy and anticoagulant therapy with warfarin was carried out. The patient was later discharged with an improvement in the painful swelling of his lower legs.
Adenocarcinoma ; Biopsy ; Bronchoscopes ; Drug Therapy ; Femoral Vein ; Humans ; Incidence ; Leg* ; Lung Neoplasms* ; Lung* ; Lymphatic Diseases ; Middle Aged ; Pericardium ; Platinum ; Prostate ; Radiography, Thoracic ; Stomach Neoplasms ; Thorax ; Thrombophlebitis ; Thrombosis ; Warfarin

BACKGROUND: The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy. PATIENTS AND METHODS: We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment. RESULTS: Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. CONCLUSION: ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy.
Adenocarcinoma ; Carcinoma, Non-Small-Cell Lung ; Drug Therapy* ; Epidermal Growth Factor ; Humans ; Korea ; Lung Neoplasms ; Phosphotransferases ; Radiography ; Skin ; Small Cell Lung Carcinoma* ; Thorax

Because a cavitary pulmonary metastasis is rare, it may not be readily identified. However, various types of cancers can metastasize to the lung in the form of cavities. We report a case of a multiple cavitary metastases to the lung from a cholangiocarcinoma in a 60-year-old man. He complained of generalized weakness and a poor oral intake for 2 months. The plain chest radiography and the chest computed tomography showed multiple small thick-walled cavities and nodules the both lungs. A bronchoscopic examination revealed a focal irregularly elevated surface of the mucosa at the orifice of the superior segment of the right lower lobe and the biopsy demonstrated an infiltrative metastatic adenocarcinoma. The abdomen-pelvis computed tomography showed an ill-marginated and irregularly low-dense area in the right lobe of the liver and a diffuse dilatation of the peripheral intrahepatic bile ducts. The esophagogastroscopy and colonoscopy showed no abnormal findings. It was concluded that the cholangiocarcinoma of the liver metastasized to the lung in the form of cavities. Thereafter, the patient underwent six cycles of the systemic chemotherapy with gemcitabine and cisplatin, and the follow-up imaging studies showed a partial response.
Adenocarcinoma ; Bile Ducts, Intrahepatic ; Biopsy ; Cholangiocarcinoma* ; Cisplatin ; Colonoscopy ; Dilatation ; Drug Therapy ; Follow-Up Studies ; Humans ; Liver ; Lung ; Middle Aged ; Mucous Membrane ; Neoplasm Metastasis* ; Radiography ; Thorax

The prognosis of unresectable advanced gastric cancer is extremely poor. We tried a neoadjuvant chemotherapy in locally advanced unresectable stomach cancer diagnosed by initial explo-laparotomy. After chemotherapy with the FADE regimen (5-fluorouracil + adriamycin + cisplatin + etoposide), the patient was diagnosed clinically as a complete response state on re-staging with radiological gastrointestinal study, fiber-gastroscopy and computerized tomography. During the second-look operation, the advanced cancer was completely resected and the pathological diagnosis was early gastric cancer (EGC) type IIc, stage II (T1N2Mo).
Adenocarcinoma/*drug therapy/radiography ; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Case Report ; Cisplatin/*administration & dosage ; Combined Modality Therapy ; Doxorubicin/*administration & dosage ; Etoposide/*administration & dosage ; Fluorouracil/*administration & dosage ; Human ; Male ; Middle Age ; Stomach/pathology/radiography ; Stomach Neoplasms/drug therapy/radiography/*surgery ; Tomography, X-Ray Computed

OBJECTIVEto investigate the pathologic basis of the difference between clinical response and pathologic response of breast carcinoma after neoadjuvant chemotherapy.

METHODStwo hundred and nine cases of breast cancer with neoadjuvant therapy were analyzed and clinical data were collected from June, 2005 to December, 2007. All patients had core needle biopsy taken before neoadjuvant chemotherapy and were operated within 4 weeks after neoadjuvant chemotherapy. Clinical examination, X-ray of breast and/or B ultrasonography of primary breast focus were taken before and after neoadjuvant chemotherapy. Clinical responses of breast primary focus were evaluated according to RECIST (response evaluation criteria in solid tumors) version 1.1.Pathologic responses of breast primary focus were evaluated according to Miller and Payne (MP) grading system. SPSS 15.0 software was used to statistical analysis.

RESULTS(1) Clinical responses basing on clinical examination showed complete response, partial response, stable disease and progressive response, in 33, 124, 41 and 11 cases respectively. (2) Eighty-seven cases had X-ray of breast taken before and after neoadjuvant chemotherapy. Clinical response basing on X-ray, showed complete response, partial response and stable disease in 8, 42 and 37 cases respectively. (3) Pathologic responses of breast primary focus were as MP1 (14 cases), MP2 (35 cases), MP3 (106 cases), MP4 (36 cases) and MP5 (18 cases). (4) The clinical response basing on clinical examination were related to the pathologic response (χ(2) = 33.668, P = 0.001); and the clinical response basing on X-ray of breast were also related to the pathologic response (χ(2) = 22.404, P = 0.004). (5) The pathologic basis of the difference between the pathologic response and the clinical response basing on X-ray of breast were: embolism of carcinoma, mucinous carcinoma, intraductal carcinoma with ossifying-type calcification, nodular fibrosis and others.

CONCLUSIONSthe clinical response may be related to the pathologic response. The difference between the two may be caused by pathologic changes. Some benign and malignant pathologic changes may contribute to the under-estimation of clinical response over pathologic response; whereas embolism of carcinoma may contribute to the over-estimation of clinical response over pathologic response.

Adenocarcinoma, Mucinous ; diagnostic imaging ; drug therapy ; pathology ; Adult ; Aged ; Breast Neoplasms ; diagnostic imaging ; drug therapy ; pathology ; Carcinoma, Ductal, Breast ; diagnostic imaging ; drug therapy ; pathology ; Carcinoma, Intraductal, Noninfiltrating ; diagnostic imaging ; drug therapy ; pathology ; Carcinoma, Lobular ; diagnostic imaging ; drug therapy ; pathology ; Disease Progression ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Radiography ; Remission Induction

The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy. We reviewed the medical records of six breast cancer patients who developed leukoencephalopathy after chemotherapy which included 5-FU and also evaluated thorough neurological examinations including mini-mental status examination, cerebrospinal fluid studies, brain images and brain biopsies. Six patients exhibited slowly progressing neurologic symptoms characterized by the impairment of cognitive function, abulia, ataxic gait, and/or akinetic mutism. None of the patients had any specific causes or etiologic factors for leukoencephalopathy. Brain MRI in all patients showed diffuse periventricular white matter changes in the T2-weighted MR image. Brain biopsy in Patient 1 showed fragmented axonal fiber and minimally deprived myelination with many scattered macrophages. Five patients who treated with steroids at the onset of neurological symptoms showed clinical improvement, regardless of their age, sex, the pathology and stage of breast cancer, or the total dosage of chemotherapeutic agents. We conclude that leukoencephalopathy in these cases could be attributable to 5-FU neurotoxicity and suggest that the administration of steroids might be the treatment of choice.
Adenocarcinoma, Mucinous/complications/drug therapy ; Adult ; Anti-Inflammatory Agents, Steroidal/therapeutic use ; Antineoplastic Agents/adverse effects/therapeutic use ; Brain/*drug effects/metabolism/radiography ; Breast Neoplasms/*complications/drug therapy ; Carcinoma, Infiltrating Duct/*complications/drug therapy ; Cyclophosphamide/adverse effects/therapeutic use ; Epirubicin/adverse effects/therapeutic use ; Female ; Fluorouracil/*adverse effects/analogs & derivatives/therapeutic use ; Glucocorticoids, Synthetic/therapeutic use ; Human ; Magnetic Resonance Imaging ; Methylprednisolone/therapeutic use ; Middle Age ; Nervous System Diseases/chemically induced/drug therapy/metabolism/radiography ; Prednisolone/therapeutic use

No abstract available.
Adenocarcinoma/*diagnosis/radiography/secondary ; Adult ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/*diagnosis/drug therapy/pathology ; Carrier Proteins/metabolism ; Doxorubicin/therapeutic use ; Drug Therapy, Combination ; Endoscopy, Digestive System ; Female ; Glycoproteins/metabolism ; Humans ; Mastectomy, Modified Radical ; Positron-Emission Tomography and Computed Tomography ; Stomach Neoplasms/*diagnosis/radiography/secondary ; Taxoids/therapeutic use ; Tomography, X-Ray Computed

To develop criteria for prostatic cancer patient care related to early diagnosis, treatment according to accurate staging and follow up in Korea, a clinical study was made on 49 patients with prostatic malignancy who were admitted to the Departrnent of Urology, Korea University College of Medicine between January 1981 and December 1985. The results were as follows 1. The incidence of prostatic malignancy was 1.6% of all inpatients, 2.2% of male inpatients and 10.1% of all male G-U tract tumors. 2. The age distribution ranged from 17 to 85 years with the highest incidence of 60 to 80 years (65%) and 3 of these 49 patients (6.1%) were men less than 40 years old. 3. The incidence of prostatic cancer has increased over the years with B.P.H. and the numbers of patients was comparable to the numbers of patients with B.P.H. during this period representing 49 and 214. 4. Prostatism (59%) and acute urinary retention (41%) were two common presenting symptoms, with symptom caused by metastasis such as persistent bone pain (14%) and pulmonary symptoms (4%). 5. On digital rectal examination at admission, 12 patients had a hard nodule in the prostate with 8 patients of multiple nodules, and 7 patients had soft, smooth prostate presumed B.P.H. 6. Of 9 tumors that extended over the prostate by Intraoperative palpation, 7 (78%) were identified by transrectal ultrasonography but only 2(22%) were identified correctly by digital rectal examination. Transrectal ultrasonography was especially useful in detecting and staging the prostatic cancer. 7. Perineal or transrectal prostatic needle biopsy was done in 29 patients. Adenocarcinoma was found in 26 patients and rhabdomyosarcoma in 3 patients. The histopathologic classification of 3 rhabdomyosarcomas was embryonal, alveolar and pleomorphic. 8. Distant metastasis was found in 28 patients (57%): The sites involved were bone in 24 patients, lymph node in 5 patients, lung in 3 patients and liver and skin in each 1 patient. The sites most frequently involved were pelvis (65%) and spine (50%) in the bony skeleton, and obturator lymph nodes (60%) in lymph node metastasis. 9. In 54% of the patients in which bone scans were positive for metastasis conventional radiographic surveys were negative. The nuclear bone scan was a highly sensitive means for detecting skeletal metastasis 50% more than the conventional bone radiography. 10. The patients were grouped according to American Urological system. 30(6l.2%) patients had stage D, 7(l4.3%) had stage C, 6(12.2%) had stage B and 6 had stage A. Of 6 patients with stage A 4 had histologically proved stage A1, 2 had stage A2. Grade III lesions made up to the largest group accounting for approximately half (47%) of the total patients. This study showed significant correlation between tumor grades and clinical stage of the disease, demonstrating a shift from lower to higher clinical stage with increasing tumor grades. 11. Patients with clinical stage B lesions were preferentially and best treated with prostatectomy, stage C with external beam radiation therapy, stage D with endocrine therapy. 3 patients with prostatic rhabdomyosarcoma were treated with radiation and systemic chemotherapy and one of these 3 patients was also treated with total cystoprostatectomy and urinary diversion. 12. Follow up study with serial measurements of acid phosphatase level and assessment of clinical status was made on 24 patients. (2l patients of adenocarcinoma, 3 patients of rhabdomyosarcoma, Of the 4 patients who had a response as determined by acid phosphates level 3 patients (75%) improved in clinical status and mean survival was more than 24 months. Of the 3 patients who had no change in acid phosphatase level 2 patients (67 %) deteriorated in clinical status and had a mean survival of 7 months. Of the 9 patients who had a progression in acid phosphatase level 7 patients (78 %) deteriorated in clinical status and had a mean survival of 10 months.
Acid Phosphatase ; Adenocarcinoma ; Adult ; Age Distribution ; Biopsy ; Biopsy, Needle ; Classification ; Digital Rectal Examination ; Drug Therapy ; Early Diagnosis ; Follow-Up Studies ; Humans ; Incidence ; Inpatients ; Korea ; Liver ; Lung ; Lymph Nodes ; Male ; Neoplasm Metastasis ; Palpation ; Patient Care ; Pelvis ; Phosphates ; Prostate ; Prostatectomy ; Prostatic Neoplasms ; Prostatism ; Radiography ; Rhabdomyosarcoma ; Skeleton ; Skin ; Spine ; Ultrasonography ; Urinary Diversion ; Urinary Retention ; Urology